Mabylon
About
What does Mabylon do?
Mabylon AG is a clinical-stage biotechnology company focused on discovering and engineering novel antibody therapeutics for allergy, inflammation, and neurology. They leverage a technology platform that rapidly identifies and clones human-derived or immunized animal antibodies from diverse immune repertoires. Mabylon aims to select the best functional, therapeutically relevant antibody products to address unmet medical needs in these areas.
What is Mabylon's revenue?
StartupHub estimates Mabylon's annual revenue at $14.7M (range $2.1M to $35.6M, 29% confidence), based on comparable companies in the sector.
What is Mabylon's valuation?
StartupHub estimates Mabylon's effective valuation at $131.2M (range $89.6M to $215.0M, 14% confidence), based on comparable companies in the sector.
How much funding has Mabylon raised?
Mabylon has raised a total of $36M in funding. The most recent round on record is Series A.
Where is Mabylon headquartered?
Mabylon is headquartered in Geneva, Switzerland.
What industry does Mabylon operate in?
Mabylon operates in Biotech, MedTech, Drug Discovery, Antibody Therapeutics, Infectious Disease, Oncology.
No comments yet. Be the first to share your take.